Director, PMDx(Precision Medicine and Diagnostics)/BM(BioMarkers) WW Oncology/Hematology Commercial Strategy and Outcomes
Posted on: 21 Oct 2022
Summit, NJ | Princeton, NJ
Job Description
At Bristol Myers Squibb, we are inspired by a single vision – transforming patients’ lives through science. In oncology, hematology, immunology and cardiovascular disease – and one of the most diverse and promising pipelines in the industry – each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Position Summary:
Reporting to the Executive Director for PMDx/BM WW Oncology/Hematology. Provide early commercial assessment for Biomarker Considerations, working with WW Commercial, finance, translational medicine, medical and other key functions in delivering options with NPVs and associated sensitivities to PMDx/BM options in Oncology and Hematology.
Key Responsibilities:
Day-to-day execution for companion and complimentary diagnostics projects in both Hematology and Oncology.
Providing PMDx/BM support for assessment of payer implications as well as establishing pharmacoeconomic assessment for value delivered to prepare for future healthcare payer assessment on key projects.
Play a key role influencing clinical in ensuring that the proper biomarker measures are incorporated into clinical trials to and help establish key marketplace value metrics including potential quality of life benefits, health care economic impact, and metrics to optimize the success of ubiquitous access if needed.
Establish and inform the organization on impact of emerging technologies like NGS, ctDNA, MRD, GEP, and PET and others that may shift the Precision Medicine landscape, the competitive environment, and this impact this may have eon both our current assets as well as assets in development.
Require a both a strong business acumen as well as a technical acumen, especially in genomics, proteomics, and metabolomics.
Qualifications & Experience:
A minimum of 8 years of experience in pharmaceutical and/or biopharma in oncology with experience in the following: precision oncology, companion diagnostics, molecular biomarkers, molecular diagnostic testing, marketing, and BD&L
Experience in tactical marketing and/or product marketing management or market development
Strong technical background in molecular biology, genomics, next generation sequencing
Prior experience with precision medicine / precision oncology/ companion diagnostics
Prior molecular diagnostic and commercial product launch experience a plus.
Strong financial acumen, outstanding negotiation skills and influence to execute.
Demonstrated analytical skills, with regards to market research and crystallization of key business insights.
? Demonstrated Cross-Functional Leadership capabilities.
Excellent oral and written communication skills.
Ability to collaborate and align with internal and external partners to develop and execute strategy.
Personal conviction, drive for results and delivery through others
The candidate will optimally possess both pharmaceutical and diagnostics experience, preferably in advanced and emerging diagnostics technologies.
BA/BS/Pharm D degree in scientific discipline required. PhD or MBA preferred.
Bristol-Myers Squibb
New York, New York
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd.
The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
-
IndustryBiopharmaceuticals
-
No. of Employees23, 300
-
Website
-
Jobs Posted1641
